Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)

Diagnostic Microbiology and Infectious Disease

Volumn 54, Issue 2, 2006, Pages 149-153

  Jones, Ronald N ^a,b   Stilwell, Matthew G ^a   Sader, Helio S ^a   Fritsche, Thomas R ^a   Goldstein, Beth P ^c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Vicuron Pharmaceuticals   (United States)

Author keywords

CR BSI; Dalbavancin; Lipoglycopeptide; Resistance; SSTI; Surveillance

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STAPHYLOCOCCUS AUREUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; GRAM POSITIVE BACTERIUM; HEALTH SURVEY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS HAEMOLYTICUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; UNITED STATES;

EID: 31744435192     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.08.015     Document Type: Article

References (17)

1. T.R. Anderegg, D.J. Biedenbach, R.N. Jones The Quality Control Working Group Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity J Clin Microbiol 41 2003 2795 2796
2. M. Buckwalter, and J.A. Powell Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide J Clin Pharmacol 2005 [in press]
3. D.J. Campoli-Richards, R.N. Brogden, and D. Faulds Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential Drugs 40 1999 449 486
4. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing Document M100-S15 2005 CLSI Wayne (PA)
5. R.G. Finch, and G.M. Eliopoulos Safety and efficacy of glycopeptide antibiotics J Antimicrob Chemother 55 Suppl S2 2005 ii5 ii13
6. R.N. Jones, D.J. Biedenbach, D.M. Johnson, and M.A. Pfaller In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent J Chemother 13 2001 244 254
7. R.N. Jones, H.S. Sader, T.R. Fritsche, and M. Stilwell Comparative activity of dalbavancin tested against 7,771 isolates from the USA and Europe (2003) Abstract E-2009 Programs and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004 American Society for Microbiology Washington (DC)
8. R.N. Jones, J.M. Streit, and T.R. Fritsche Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide Int J Antimicrob Agents 23 2004 197 199
9. A. Leighton, A.B. Gottlieb, and M.B. Dorr Tolerability, pharmacokinetics and pharmacodynamics of intravenous dalbavancin in healthy volunteers Antimicrob Agents Chemother 48 2004 940 945
10. S. Lopez, C. Hackbarth, G. Romano, J. Trias, D. Jabes, and B.P. Goldstein In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide J Antimicrob Chemother 55 Suppl S2 2005 ii21 ii24
11. A. Malabarba, and B.P. Goldstein Origin, structure and activity in vitro and in vivo of dalbavancin J Antimicrob Chemother 55 Suppl S2 2005 ii15 ii20
12. S. Mushtaq, M. Warner, A.P. Johnson, and D.M. Livermore Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods J Antimicrob Chemother 54 2004 617 620
13. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Document M7-A6 2003 NCCLS Wayne (PA)
14. I. Raad, R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, H. Hanna, B. Goldstein, T. Henkel, and E. Seltzer Efficacy and safety of weekly dalbavancin in the treatment of catheter-related bloodstream infections Clin Infect Dis 40 2005 374 380
15. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, and T. Henkel Once-weekly dalbavancin versus standard of care antimicrobial regimens for treatment of skin and soft tissue infections Clin Infect Dis 37 2003 1298 1303
16. J.M. Streit, T.R. Fritsche, H.S. Sader, and R.N. Jones Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates Diagn Microbiol Infect Dis 48 2004 137 143
17. N. Woodford Novel agents for the treatment of resistant Gram-positive infections Expert Opin Investig Drugs 12 2003 117 137